Loading...
XLONCIZ
Market cap7mUSD
Dec 24, Last price  
1.55GBP
1D
0.00%
1Q
-26.19%
IPO
-83.47%
Name

Cizzle Biotechnology Holdings PLC

Chart & Performance

D1W1MN
XLON:CIZ chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
7.02%
Rev. gr., 5y
-55.19%
Revenues
0k
222,000307,0001,628,0001,561,0002,720,0006,061,0008,701,0009,423,0007,188,0006,901,0005,319,0004,547,00074,00000000
Net income
-2k
L-99.81%
-1,453,000-1,865,000-1,342,000-369,000-886,000-1,024,000-780,000-651,000-1,332,000-2,767,000-1,167,000-1,910,000-2,057,000-21,706-306,000-3,921,000-912,000-1,717
CFO
-639k
L-26.72%
-1,097,000-2,095,000-1,549,000-150,000-305,000-1,510,000-145,000-678,000-526,000-570,000186,000-190,000-513,000-7,072-294,000-1,009,000-872,000-639,000

Profile

Cizzle Biotechnology Holdings Plc engages in development of an immunoassay test for the CIZ1B biomarker for the early detection of lung cancer. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings Plc is headquartered in London, the United Kingdom.
URL
https://cizzlebiotechnology.com/
IPO date
May 23, 2007
Employees
4
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
1
661
427
Unusual Expense (Income)
NOPBT
(1)
(661)
(427)
NOPBT Margin
Operating Taxes
(46)
(51)
(37)
Tax Rate
NOPAT
45
(610)
(390)
Net income
(2)
-99.81%
(912)
-76.74%
(3,921)
1,181.37%
Dividends
Dividend yield
Proceeds from repurchase of equity
305
595
2,041
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
41
Net debt
(1,557)
(478)
(875)
Cash flow
Cash from operating activities
(639)
(872)
(1,009)
CAPEX
(200)
Cash from investing activities
(120)
(154)
Cash from financing activities
305
595
2,031
FCF
127
(692)
(390)
Balance
Cash
1,557
478
875
Long term investments
Excess cash
1,557
478
875
Stockholders' equity
(4,366)
4,277
6,163
Invested Capital
5,873
2,154
19
ROIC
1.12%
ROCE
EV
Common stock shares outstanding
355,861
291,323
160,516
Price
Market cap
EV
EBITDA
(1)
(661)
(427)
EV/EBITDA
Interest
Interest/NOPBT